ERBB2 and breast carcinoma: During the past decades, radiolabeled peptides have been investigated as potential therapeutic agents, both in research and in clinic; for example, 188Re-HYNIC-trastuzumab enhanced the effect of apoptosis in HER2-overexpressing breast cancer cells and 188Re-labeled HEDP could be used for internal radiation therapy to treat painful bone metastases28, 29.